{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:13:30Z","timestamp":1790090010932,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02581-z","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:36:00Z","timestamp":1771932960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Coronary atherosclerotic plaque intervention with Tongxinluo capsule (TXL-CAP): a multicenter, randomized, double-blind and placebo-controlled study"],"prefix":"10.1038","volume":"11","author":[{"given":"Mei","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Ti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayue Darrel","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranzun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peili","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4432-6144","authenticated-orcid":false,"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3672-6543","authenticated-orcid":false,"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the TXL-CAP Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peili","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengming","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2581_CR1","doi-asserted-by":"publisher","first-page":"e2110660","DOI":"10.1002\/adma.202110660","volume":"34","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. Targeting the microenvironment of vulnerable atherosclerotic plaques: an emerging diagnosis and therapy strategy for atherosclerosis. Adv. Mater. 34, e2110660 (2022).","journal-title":"Adv. Mater."},{"key":"2581_CR2","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","volume":"47","author":"E Falk","year":"2006","unstructured":"Falk, E. Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol. 47, C7\u2013C12 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2581_CR3","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(24)00413-6","volume":"403","author":"SJ Park","year":"2024","unstructured":"Park, S. J. et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet 403, 1753\u20131765 (2024).","journal-title":"Lancet"},{"key":"2581_CR4","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1093\/eurheartj\/ehn356","volume":"29","author":"G Pundziute","year":"2008","unstructured":"Pundziute, G. et al. Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis. Eur. Heart J. 29, 2373\u20132381 (2008).","journal-title":"Eur. Heart J."},{"key":"2581_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41569-022-00769-8","volume":"20","author":"P Gaba","year":"2023","unstructured":"Gaba, P., Gersh, B. J., Muller, J., Narula, J. & Stone, G. W. Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. Nat. Rev. Cardiol. 20, 181\u2013196 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"2581_CR6","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1056\/NEJM199705013361802","volume":"336","author":"AP Burke","year":"1997","unstructured":"Burke, A. P. et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N. Engl. J. Med. 336, 1276\u20131282 (1997).","journal-title":"N. Engl. J. Med."},{"key":"2581_CR7","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/eurheartj\/ehq518","volume":"32","author":"T Yonetsu","year":"2011","unstructured":"Yonetsu, T. et al. In vivo critical fibrous cap thickness for rupture-prone coronary plaques assessed by optical coherence tomography. Eur. Heart J. 32, 1251\u20131259 (2011).","journal-title":"Eur. Heart J."},{"key":"2581_CR8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41569-022-00687-9","volume":"19","author":"M Araki","year":"2022","unstructured":"Araki, M. et al. Optical coherence tomography in coronary atherosclerosis assessment and intervention. Nat. Rev. Cardiol. 19, 684\u2013703 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"2581_CR9","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1161\/01.CIR.0000087480.94275.97","volume":"108","author":"M Naghavi","year":"2003","unstructured":"Naghavi, M. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108, 1664\u20131672 (2003).","journal-title":"Circulation"},{"key":"2581_CR10","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber, L. et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: The PACMAN-AMI randomized clinical trial. JAMA 327, 1771\u20131781 (2022).","journal-title":"JAMA"},{"key":"2581_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jjcc.2019.08.002","volume":"75","author":"H Yano","year":"2020","unstructured":"Yano, H., Horinaka, S. & Ishimitsu, T. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J. Cardiol. 75, 289\u2013295 (2020).","journal-title":"J. Cardiol."},{"key":"2581_CR12","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls, S. J. et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imag. 15, 1308\u20131321 (2022).","journal-title":"JACC Cardiovasc Imag."},{"key":"2581_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","volume":"67","author":"RC Hoogeveen","year":"2021","unstructured":"Hoogeveen, R. C. & Ballantyne, C. M. Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. Clin. Chem. 67, 143\u2013153 (2021).","journal-title":"Clin. Chem."},{"key":"2581_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0140-6736(21)00249-X","volume":"397","author":"D Erlinge","year":"2021","unstructured":"Erlinge, D. et al. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet 397, 985\u2013995 (2021).","journal-title":"Lancet"},{"key":"2581_CR15","doi-asserted-by":"publisher","first-page":"H1967","DOI":"10.1152\/ajpheart.00944.2009","volume":"297","author":"LD Karalliedde","year":"2009","unstructured":"Karalliedde, L. D. & Kappagoda, C. T. The challenge of traditional Chinese medicines for allopathic practitioners. Am. J. Physiol. Heart Circ. Physiol. 297, H1967\u2013H1969 (2009).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2581_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jep.2009.04.009","volume":"124","author":"WQ Chen","year":"2009","unstructured":"Chen, W. Q. et al. Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model. J. Ethnopharmacol. 124, 103\u2013110 (2009).","journal-title":"J. Ethnopharmacol."},{"key":"2581_CR17","doi-asserted-by":"publisher","first-page":"H2004","DOI":"10.1152\/ajpheart.00208.2009","volume":"297","author":"L Zhang","year":"2009","unstructured":"Zhang, L. et al. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy. Am. J. Physiol. Heart Circ. Physiol. 297, H2004\u2013H2014 (2009).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2581_CR18","doi-asserted-by":"publisher","first-page":"B13","DOI":"10.1093\/eurheartj\/suv020","volume":"17","author":"L Ma","year":"2015","unstructured":"Ma, L. et al. Traditional Chinese medication Tongxinluo inhibits inflammatory angiogenesis via Bmx\/NF-\u03baB\/MAPK pathways. Eur. Heart J. Suppl. 17, B13\u2013B22 (2015).","journal-title":"Eur. Heart J. Suppl."},{"key":"2581_CR19","doi-asserted-by":"publisher","first-page":"805266","DOI":"10.3389\/fphar.2022.805266","volume":"13","author":"Y Qi","year":"2022","unstructured":"Qi, Y. et al. Tongxinluo may alleviate inflammation and improve the stability of atherosclerotic plaques by changing the intestinal flora. Front Pharm. 13, 805266 (2022).","journal-title":"Front Pharm."},{"key":"2581_CR20","doi-asserted-by":"publisher","first-page":"673366","DOI":"10.3389\/fphar.2021.673366","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Traditional Chinese medication tongxinluo attenuates lipidosis in Ox-LDL-stimulated macrophages by enhancing beclin-1-induced autophagy. Front Pharm. 12, 673366 (2021).","journal-title":"Front Pharm."},{"key":"2581_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41118-z","volume":"9","author":"M Zhang","year":"2019","unstructured":"Zhang, M. et al. Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): A multicenter randomized double-blind parallel-group placebo-controlled study. Sci. Rep. 9, 4545 (2019).","journal-title":"Sci. Rep."},{"key":"2581_CR22","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2023.19524","volume":"330","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Traditional Chinese medicine compound (tongxinluo) and clinical outcomes of patients with acute myocardial infarction: the CTS-AMI randomized clinical trial. JAMA 330, 1534\u20131545 (2023).","journal-title":"JAMA"},{"key":"2581_CR23","first-page":"833","volume":"44","author":"Joint committee issued Chinese guideline for the management of dyslipidemia in adults","year":"2016","unstructured":"Joint committee issued Chinese guideline for the management of dyslipidemia in adults Zhonghua Xin Xue Guan Bing. Za Zhi 44, 833\u2013853 (2016).","journal-title":"Zhonghua Xin Xue Guan Bing. Za Zhi"},{"key":"2581_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.jacc.2011.09.079","volume":"59","author":"GJ Tearney","year":"2012","unstructured":"Tearney, G. J. et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J. Am. Coll. Cardiol. 59, 1058\u20131072 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2581_CR25","doi-asserted-by":"crossref","unstructured":"Biccir\u00e8, F. G. et al. Effects of lipid lowering therapies on vulnerable plaque features: an updated narrative review of the literature. J. Cardiovasc. Dev. Dis. 10 (2023).","DOI":"10.3390\/jcdd10060260"},{"key":"2581_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","volume":"120","author":"F Gomez-Delgado","year":"2024","unstructured":"Gomez-Delgado, F., Raya-Cruz, M., Katsiki, N., Delgado-Lista, J. & Perez-Martinez, P. Residual cardiovascular risk: When should we treat it? Eur. J. Intern. Med. 120, 17\u201324 (2024).","journal-title":"Eur. J. Intern. Med."},{"key":"2581_CR27","doi-asserted-by":"crossref","unstructured":"Wu, T. et al. Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris. Cochrane Database Syst. Rev. 2006, Cd004474 (2006).","DOI":"10.1002\/14651858.CD004474.pub2"},{"key":"2581_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12933-014-0117-8","volume":"13","author":"M Burgmaier","year":"2014","unstructured":"Burgmaier, M., Hellmich, M., Marx, N. & Reith, S. A score to quantify coronary plaque vulnerability in high-risk patients with type 2 diabetes: an optical coherence tomography study. Cardiovasc Diabetol. 13, 117 (2014).","journal-title":"Cardiovasc Diabetol."},{"key":"2581_CR29","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(19)31794-5","volume":"394","author":"R Waksman","year":"2019","unstructured":"Waksman, R. et al. Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. Lancet 394, 1629\u20131637 (2019).","journal-title":"Lancet"},{"key":"2581_CR30","doi-asserted-by":"crossref","unstructured":"Patti, G. et al. Modifications of coronary plaque phenotype on lipid-lowering therapies and risk of cardiovascular events: a systematic review and meta-regression analysis. Atherosclerosis, 120433 (2025).","DOI":"10.1016\/j.atherosclerosis.2025.120433"},{"key":"2581_CR31","unstructured":"Joint Committee on the Chinese Guidelines for Lipid Management. Zhonghua Xin Xue Guan Bing Za Zhi 51, 221-255 (2023)."},{"key":"2581_CR32","doi-asserted-by":"publisher","first-page":"108767","DOI":"10.1016\/j.biopha.2019.108767","volume":"113","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. Tongxinluo may stabilize atherosclerotic plaque via multiple mechanisms scanning by GeneChip. Biomed. Pharmacother. 113, 108767 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"2581_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jep.2010.10.031","volume":"133","author":"JQ Liang","year":"2011","unstructured":"Liang, J. Q. et al. Chinese medicine Tongxinluo modulates vascular endothelial function by inducing eNOS expression via the PI-3K\/Akt\/HIF-dependent signaling pathway. J. Ethnopharmacol. 133, 517\u2013523 (2011).","journal-title":"J. Ethnopharmacol."},{"key":"2581_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.26599\/1671-5411.2025.07.004","volume":"22","author":"M Ni","year":"2025","unstructured":"Ni, M. et al. Study design and rationale of the TXL-CAP trial: a randomized, double-blind, placebo-controlled, multicenter clinical trial assessing the effect of Tongxinluo capsules on the stability of coronary atherosclerotic plaques. J. Geriatr. Cardiol. 22, 615\u2013624 (2025).","journal-title":"J. Geriatr. Cardiol."},{"key":"2581_CR35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi, M. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur. Heart J. 37, 267\u2013315 (2016).","journal-title":"Eur. Heart J."},{"key":"2581_CR36","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jacc.2007.04.082","volume":"50","author":"T Kubo","year":"2007","unstructured":"Kubo, T. et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J. Am. Coll. Cardiol. 50, 933\u2013939 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2581_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jjcc.2018.03.003","volume":"72","author":"K Fujii","year":"2018","unstructured":"Fujii, K., Kawakami, R. & Hirota, S. Histopathological validation of optical coherence tomography findings of the coronary arteries. J. Cardiol. 72, 179\u2013185 (2018).","journal-title":"J. Cardiol."},{"key":"2581_CR38","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jacc.2023.01.030","volume":"81","author":"S Jiang","year":"2023","unstructured":"Jiang, S. et al. Identification of high-risk coronary lesions by 3-vessel optical coherence tomography. J. Am. Coll. Cardiol. 81, 1217\u20131230 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2581_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.atherosclerosis.2016.02.010","volume":"247","author":"J Dai","year":"2016","unstructured":"Dai, J. et al. Association between cholesterol crystals and culprit lesion vulnerability in patients with acute coronary syndrome: An optical coherence tomography study. Atherosclerosis 247, 111\u2013117 (2016).","journal-title":"Atherosclerosis"},{"key":"2581_CR40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1056\/NEJMoa1402556","volume":"372","author":"S Verheye","year":"2015","unstructured":"Verheye, S. et al. Efficacy of a device to narrow the coronary sinus in refractory angina. N. Engl. J. Med 372, 519\u2013527 (2015).","journal-title":"N. Engl. J. Med"},{"key":"2581_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.115.019768","volume":"133","author":"KP Alexander","year":"2016","unstructured":"Alexander, K. P. et al. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) Trial. Circulation 133, 39\u201347 (2016).","journal-title":"Circulation"},{"key":"2581_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.amjcard.2013.10.038","volume":"113","author":"M Habara","year":"2014","unstructured":"Habara, M. et al. Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe. Am. J. Cardiol. 113, 580\u2013587 (2014).","journal-title":"Am. J. Cardiol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02581-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02581-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02581-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:06:18Z","timestamp":1771977978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02581-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2581"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02581-z","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}